MAZELSKY JONATHAN JAY 4

4 · IDEXX LABORATORIES INC /DE · Filed Feb 17, 2026

AI-generated summary of this filing

Updated Feb 18, 2026

IDEXX (IDXX) CEO Jonathan Mazelsky Sells 915 Shares for $575.9K

What Happened

Jonathan J. Mazelsky, President & CEO of IDEXX Laboratories (IDXX), converted/received vested derivative awards and had 915 shares sold to satisfy tax withholding. On Feb 14, 2026 he converted/converted two derivative awards (958 and 1,099 shares; total 2,057 shares) and 915 of the resulting shares were disposed (sold) at $629.35 per share for $575,855 to cover tax liabilities. On Feb 12, 2026 he was granted 13,407 restricted stock units (RSUs) that will be deferred under IDEXX’s Deferred Compensation Plan and vest in three annual installments beginning Feb 14, 2027.

Key Details

Transaction dates: RSU grant 2026-02-12; conversions and tax-withholding sale 2026-02-14. Filing date: 2026-02-17.
Prices/values: Tax-withholding sale of 915 shares at $629.35 = $575,855 (F2 = Feb 13, 2026 closing price). Conversions of derivatives recorded at $0 (typical for RSU/derivative conversions).
Grant specifics: 13,407 RSUs deferred and vest in three annual installments beginning 2/14/2027 (F3). Other referenced RSUs vested in installments beginning 2023 and 2024 (F4, F5).
ESPP note: Filing notes 1,943.302 shares held in the company ESPP (includes 21 shares purchased in late 2025) (F1).
Shares owned after transactions: Not specified in the filing.
Timeliness: Form 4 filed Feb 17, 2026; the filing does not indicate it was late.

Context

This was mostly a conversion/settlement of vested derivative awards and a routine sell-to-cover tax withholding. Converting RSUs (recorded as derivative exercise/conversion) and selling a portion to cover taxes is common and not necessarily a signal about the CEO’s view on the stock. Purchases tend to be more informative than routine tax-withholding sales.

Form 4

Period: 2026-02-12

DirectorPresident and CEO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-02-14+958→ 83,422.302 total
Exercise/Conversion
Common Stock
2026-02-14+1,099→ 84,521.302 total
Tax Payment
Common Stock
[F2]
2026-02-14$629.35/sh−915$575,855→ 83,606.302 total
Award
Restricted Stock Unit
[F3]
2026-02-12+13,407→ 13,407 total
→ Common Stock (13,407 underlying)
Exercise/Conversion
Restricted Stock Unit
[F4]
2026-02-14−958→ 0 total
→ Common Stock (958 underlying)
Exercise/Conversion
Restricted Stock Unit
[F5]
2026-02-14−1,099→ 1,099 total
→ Common Stock (1,099 underlying)

Footnotes (5)

[F1]Includes a total of 21 shares purchased under the Issuer's Employee Stock Purchase Plan ('ESPP') on September 30, 2025 and December 31, 2025. There are a total of 1,943.302 shares held in the ESPP which has been increased by 0.004 shares due to a rounding calculation of previously issued fractional shares.
[F2]Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
[F3]Grant of restricted stock units ('RSU') that upon vesting, will be deferred and recorded in an account under the Issuer's Deferred Compensation Plan. This RSU grant vests in three annual installments, beginning February 14, 2027.
[F4]Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023.
[F5]Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.

Signature

/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky|2026-02-17

1 file